FIELD: molecular medicine; pharmacology.
SUBSTANCE: invention relates to the field of molecular medicine and pharmacology, namely to a liposomal form of Abies sibirica resin. A method for obtaining the liposomal form of Abies sibirica resin, which is phospholipid membrane with the inclusion of natural Abies sibirica resin (oleoresin) in amount of up to 1% by wt., is proposed including following stages: simple mixing of 0.55 g of phospholipid, 0.03 g of cholesterol, 0.04 g of a pegylating agent - up to 6% by wt. and active substance - Abies sibirica resin - up to 1% by wt. in a suitable solvent, evaporation of the solvent at a temperature above a phospholipid phase transition to obtain homogeneous lipid film, its rehydration in a medium selected from ultra-purified water or a physiological 0.9% aqueous solution of sodium chloride - up to 100% by wt., while mixing at a constant temperature above the phospholipid phase transition and subsequent dispersion of particles to a size of about 100 nm. The liposomal form of Abies sibirica resin obtained by the above-described method has an activity selected from: a function of directed delivery of biologically active substance of Abies sibirica oleoresin to the brain, antioxidant activity in vitro, cytotoxic activity in vitro against human tumor cells M-Hela. The liposomal form of Abies sibirica resin is used to ensure the activity selected from: penetration into the central nervous system (CNS), penetration into the CNS with intranasal administration, antioxidant activity in vitro, cytotoxic activity in vitro against human tumor cells M-Hela.
EFFECT: above-described liposomal form of Abies sibirica resin has an increased bioavailability of Abies sibirica resin, which is water-soluble, is capable of non-invasively penetrating the CNS and at the same time has pharmacological activity, simultaneously exhibiting in vitro antioxidant properties and cytotoxic activity against cervical cancer cells M-Hela.
8 cl, 15 dwg, 3 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
POLYACTIVE TERPENOID SUBSTANCE ABISIL-2, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND WAYS OF ITS APPLICATION | 2007 |
|
RU2338547C1 |
SODIUM COBALT POLYGALACTURONATE WITH ANTITUMOR ACTIVITY | 2023 |
|
RU2794885C1 |
METHOD FOR STIMULATING MITOPHAGY AND AUTOPHAGY IN CELLS, METHOD FOR STIMULATING AUTOPHAGY OR MITOPHAGY FOR TREATING A CONDITION ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION | 2020 |
|
RU2765414C1 |
USE OF L-CARNOSINE FOR PRODUCING NANOPREPARATION POSSESSING ANTIHYPOXIC AND ANTIOXIDANT ACTIVITY | 2012 |
|
RU2482867C1 |
ANTITUMOR AGENTS BASED ON MACRO- AND MICROELEMENT-CONTAINING POLYGALACTURONATES (OPTIONS) | 2022 |
|
RU2792613C1 |
16-(1,2,4-OXADIAZOL-3-YL)-15,16-EPOXILABDANOIDS POSSESSING CYTOTOXIC ACTIVITY ON HUMAN TUMOUR CELLS | 2011 |
|
RU2473550C1 |
NEW STERICALLY HINDERED PHENOLS CONTAINING BENZOFUROXAN FRAGMENTS WITH ANTITUMOR ACTIVITY | 2022 |
|
RU2796810C1 |
METHOD OF DETERMINING ANTI-OXIDANT ACTIVITY OF ESSENTIAL OIL OF VEGETABLE ORIGIN in vitro | 2013 |
|
RU2526125C1 |
BROMINE-CONTAINING STERICALLY HINDERED PHENOLS WITH ANTICANCER ACTIVITY | 2023 |
|
RU2822270C1 |
AGENT POSSESSING CYTOTOXIC ACTIVITY | 2019 |
|
RU2714932C1 |
Authors
Dates
2021-10-22—Published
2019-12-03—Filed